Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets

Holly Meany, Brigitte C. Widemann, Nancy Ratner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.

Original languageEnglish (US)
Title of host publicationNeurofibromatosis Type 1: Molecular and Cellular Biology
PublisherSpringer-Verlag Berlin Heidelberg
Pages445-467
Number of pages23
Volume9783642328640
ISBN (Print)9783642328640, 3642328636, 9783642328633
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Neurilemmoma
Tumors
Therapeutics
Neoplasms
Epidemiology

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Meany, H., Widemann, B. C., & Ratner, N. (2012). Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets. In Neurofibromatosis Type 1: Molecular and Cellular Biology (Vol. 9783642328640, pp. 445-467). Springer-Verlag Berlin Heidelberg. https://doi.org/10.1007/978-3-642-32864-0_29

Malignant peripheral nerve sheath tumors : Prognostic and diagnostic markers and therapeutic targets. / Meany, Holly; Widemann, Brigitte C.; Ratner, Nancy.

Neurofibromatosis Type 1: Molecular and Cellular Biology. Vol. 9783642328640 Springer-Verlag Berlin Heidelberg, 2012. p. 445-467.

Research output: Chapter in Book/Report/Conference proceedingChapter

Meany, H, Widemann, BC & Ratner, N 2012, Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets. in Neurofibromatosis Type 1: Molecular and Cellular Biology. vol. 9783642328640, Springer-Verlag Berlin Heidelberg, pp. 445-467. https://doi.org/10.1007/978-3-642-32864-0_29
Meany H, Widemann BC, Ratner N. Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets. In Neurofibromatosis Type 1: Molecular and Cellular Biology. Vol. 9783642328640. Springer-Verlag Berlin Heidelberg. 2012. p. 445-467 https://doi.org/10.1007/978-3-642-32864-0_29
Meany, Holly ; Widemann, Brigitte C. ; Ratner, Nancy. / Malignant peripheral nerve sheath tumors : Prognostic and diagnostic markers and therapeutic targets. Neurofibromatosis Type 1: Molecular and Cellular Biology. Vol. 9783642328640 Springer-Verlag Berlin Heidelberg, 2012. pp. 445-467
@inbook{74129d0918544d66aca817e2e3193a20,
title = "Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets",
abstract = "Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 {\%} of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.",
author = "Holly Meany and Widemann, {Brigitte C.} and Nancy Ratner",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/978-3-642-32864-0_29",
language = "English (US)",
isbn = "9783642328640",
volume = "9783642328640",
pages = "445--467",
booktitle = "Neurofibromatosis Type 1: Molecular and Cellular Biology",
publisher = "Springer-Verlag Berlin Heidelberg",

}

TY - CHAP

T1 - Malignant peripheral nerve sheath tumors

T2 - Prognostic and diagnostic markers and therapeutic targets

AU - Meany, Holly

AU - Widemann, Brigitte C.

AU - Ratner, Nancy

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.

AB - Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.

UR - http://www.scopus.com/inward/record.url?scp=84885751067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885751067&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-32864-0_29

DO - 10.1007/978-3-642-32864-0_29

M3 - Chapter

AN - SCOPUS:84885751067

SN - 9783642328640

SN - 3642328636

SN - 9783642328633

VL - 9783642328640

SP - 445

EP - 467

BT - Neurofibromatosis Type 1: Molecular and Cellular Biology

PB - Springer-Verlag Berlin Heidelberg

ER -